Další formáty:
BibTeX
LaTeX
RIS
@article{1159178,
author = {Ludwig, Heinz and Kasparu, Hedwig and Leitgeb, Clemens and Rauch, Elisabeth and Linkesch, Werner and Zojer, Niklas and Greil, Richard and Seebacher, Adelheid and Pour, Luděk and Weißmann, Adalbert and Adam, Zdeněk},
article_location = {WASHINGTON},
article_number = {7},
doi = {http://dx.doi.org/10.1182/blood-2013-08-521468},
keywords = {Bendamustine; bortezomib; dexamethasone; relapsed/refractory myeloma},
language = {eng},
issn = {0006-4971},
journal = {Blood},
title = {Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma},
volume = {123},
year = {2014}
}
TY - JOUR
ID - 1159178
AU - Ludwig, Heinz - Kasparu, Hedwig - Leitgeb, Clemens - Rauch, Elisabeth - Linkesch, Werner - Zojer, Niklas - Greil, Richard - Seebacher, Adelheid - Pour, Luděk - Weißmann, Adalbert - Adam, Zdeněk
PY - 2014
TI - Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma
JF - Blood
VL - 123
IS - 7
SP - 985-991
EP - 985-991
PB - American Society of Hematology
SN - 00064971
KW - Bendamustine
KW - bortezomib
KW - dexamethasone
KW - relapsed/refractory myeloma
N2 - Bendamustine with bortezomib and dexamethasone was evaluated in 79 patients with relapsed/refractory multiple myeloma. Median age was 64 (range 40-80) years and patients had a median of 2 (range 1-6) prior treatment lines. Bendamustine 70 mg/m2, day 1 and 4, bortezomib 1.3mg/m2 days 1, 4, 8, 11 intravenously, and dexamethasone 20 mg, days 1, 4, 8, and 11, q 28 days, was given for up to 8 cycles. Primary endpoint was response rate (ORR) and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to response and toxicity. ORR was 60.9%, and when minor responses were included, 75.9%. Median time to response was 31 days (111 to best response). ORR rate was similar in patients previously exposed to bortezomib, lenalidomide and to both bortezomib and lenalidomide. PFS was 9.7 and OS 25.6 months. Multivariate analysis showed high LDH, >/-3 prior treatment lines and low platelet counts correlating with short survival. Grade 3/4 thrombopenia and G 3/4/5 infections were noted in 38% and 23% respectively. Grade
ER -
LUDWIG, Heinz, Hedwig KASPARU, Clemens LEITGEB, Elisabeth RAUCH, Werner LINKESCH, Niklas ZOJER, Richard GREIL, Adelheid SEEBACHER, Luděk POUR, Adalbert WEISSMANN a Zdeněk ADAM. Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. \textit{Blood}. WASHINGTON: American Society of Hematology, 2014, roč.~123, č.~7, s.~985-991. ISSN~0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood-2013-08-521468.
|
